Semuloparin reduces rate of VTE in orthopedic surgery patients, investigation finds
McMaster University researcher leads ecumenical workroom
An ultra-low-molecular-weight heparin called semuloparin has been set to compress the number of venous thromboembolism in orthopedic surgery patients in a most of all clinical program being surpass most of all a steering council chaired in particular McMaster University professor Dr. Alexander Turpie.
The follow-up investigation of three recently completed global clinical studies on short-term venous thromboembolism (VTE) vigilant drug in patients undergoing grave orthopedic surgery demonstrated that the ultra-low-molecular-weight heparin semuloparin reduced the occurrence of VTE and all-cause end via 25 per cent compared to the commonly occupied psychoanalysis sedate enoxaparin (a low-molecular-weight heparin).
Patients undergoing pre-eminent orthopedic surgery are at increased peril of developing a rickety blood clot that blocks veins, which is known as venous thromboembolism (VTE). Without treatment, the prevalence of confirmed deep-vein thrombosis, blood clots within the veins of the legs and pelvis, is up to 40 to 60 per cent following significant orthopedic surgery.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
